A cluster of analyst target cuts in the days before iRhythm's May 7 earnings report frames a clear question: has the Street's confidence in the growth story been structurally trimmed, or does the recent de-rating leave room for a positive surprise?
The analyst picture is the dominant pre-earnings narrative for IRTC. Four firms cut targets on May 1 alone — JP Morgan moved from $215 to $175, Wells Fargo from $200 to $180, Canaccord from $198 to $180, and Evercore ISI from $170 to $160 — all while holding positive ratings. Citi went the other direction just last Friday, nudging its target up from $155 to $157 with a Buy. Goldman Sachs, which is neutral, had already cut from $184 to $147 in early April. The net effect is a mean consensus target of $183.50 against a current price of $119.18. That gap — roughly 54% — reflects genuine bullish conviction from most of the Street, though the direction of travel on individual targets has been predominantly downward.
The bull case rests on volume momentum. Record testing volumes in 2025 underpinned strong revenue and EBITDA guidance for 2026, with management targeting 17–18% revenue growth and a low double-digit EBITDA margin. Bulls point to Zio MCT product launches, primary care channel expansion, and nascent international optionality as sources of upside beyond the base case. Bears push back that revenue growth is decelerating, profitability remains thin at an EV/EBITDA of roughly 32.8x, and the company's CMS reimbursement exposure creates an overhang that newer product launches won't fully offset in the near term. The PE multiple of 277x reflects a stock priced for a long runway — leaving little cushion if execution misses.
Short positioning is a secondary angle, not the lead story. SI runs at 9.2% of the free float, up roughly 3.8% over the past month, with days to cover near 7.8 — meaningful but not extreme. Borrow availability is wide open at just 0.45% cost to borrow, and availability remains ample. There is no sign of squeeze mechanics building ahead of the release. Options are modestly more defensive than usual: the put/call ratio is 1.54, above its 20-day average of 1.27, though at less than one standard deviation above the mean it does not signal unusual fear. The stock has dropped 5.4% on the week and sits roughly 35% below its 52-week highs, which means the entry point for new longs looks more attractive than it did in early 2026 — but also that the stock has already been repriced lower. The one data point worth flagging from earnings history: the February 2026 print triggered an 11% single-day drop and a 15.8% five-day decline, a reminder that IRTC can move sharply on disappointing numbers.
The May 7 print is therefore a test of whether 2026 guidance holds — and whether the company can demonstrate margin progress convincing enough to justify the premium multiple that a still-bullish analyst consensus is pricing in.
See the live data behind this article on ORTEX.
Open IRTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
